Labcorp selected for biomarker testing in Florida prostate-cancer study
OTraces plans to test about 950 men under a US$2M state grant that ends in March 2027; Labcorp's fee is undisclosed.

A prostate-cancer study will send samples from about 950 men to Labcorp Holdings Inc. NYSELH after OTraces announced the laboratory's selection on Wednesday. The wider project carries a US$2 million Florida grant, but Labcorp's fee is undisclosed.
Under the Nov. 18 announcement, Labcorp will measure five serum biomarkers for the OTraces prostate-cancer platform. The existing grant term ends March 31, 2027. OTraces will interpret the laboratory measurements through its own information system and proprietary algorithm to estimate the likelihood of clinically significant cancer.
Labcorp is a large North Carolina laboratory-services company supplying diagnostic and drug-development testing worldwide.
The available Google Finance quote puts Labcorp's Nov. 16 close at US$372.46 in New York at 4:00 p.m. EST NYSELH. That price predates Wednesday's announcement and establishes no reaction to the assignment.
Biopsy Results Will Be The Reference Standard
Participants must have prostate-specific antigen, or PSA, levels of at least 3 nanograms per millilitre and already be scheduled for a prostate biopsy. Each will receive the OTraces blood test and a standard-of-care biopsy, allowing the test's predictions to be compared with tissue findings.
In its June 25 grant announcement, posted on its website June 30, OTraces described a prospective, multicentre, blinded diagnostic accuracy study. The primary objective is to assess whether the platform predicts biopsy outcomes better than standard PSA testing.
OTraces says it will also analyse how measurements of each biomarker relate to biopsy findings. The study will also assess whether the test can tell aggressive cancer from indolent disease. The intended reduction in unnecessary biopsies remains an objective to be tested; Wednesday's release reports no diagnostic accuracy results.
Read more: Telo Genomics discloses option for worldwide AI cancer-cell licence
Labcorp will measure PSA alongside interleukin-6, interleukin-8, tumour necrosis factor-alpha and vascular endothelial growth factor. OTraces says all grant-funded research and laboratory work must take place in Florida under Contract 26C07.
"By centralizing biomarker testing at Labcorp, we can streamline sample logistics, harmonize processes across Florida sites and generate a robust dataset suitable for clinical validation and eventual commercialization," OTraces president Alain Cappeluti said in the release.
Labcorp Has Also Agreed To Buy 4Kscore
An existing prostate-cancer blood test is part of Labcorp's Oct. 15 agreement with OPKO Health, Inc. NASDAQOPK to buy selected BioReference Health assets. The companies say the assets include 4Kscore, an FDA-approved test used to evaluate aggressive prostate-cancer risk when deciding whether to perform a biopsy.
The companies announced US$722 million in cash at closing and up to US$150 million in additional payments tied to 4Kscore revenue on Oct. 15. Labcorp's Oct. 28 results still listed the acquisition as subject to regulatory approvals and customary closing conditions.
OPKO shares NASDAQOPK closed at US$1.62 on Nov. 17 in New York at 4:00 p.m. EST, according to Google Finance. That dated peer quote also precedes the Nov. 18 announcement.
For scale, Labcorp reported third-quarter revenue of US$3.81 billion on Oct. 28. Without a disclosed testing fee, the Florida grant supplies no measure of incremental revenue for the listed laboratory operator.
Labcorp's cancer-testing partnerships also include ColoSense, developed by privately held Geneoscopy. In a June 22 joint release, Labcorp announced nationwide availability of that FDA-approved RNA-based colorectal cancer screening test.
Read more: Geneoscopy settles Delaware litigation with Abbott's Exact Sciences
The next fixed study deadline is March 31, 2027, when Contract 26C07's grant term ends, according to OTraces' June announcement. The funding is tied to research and reporting deliverables; Wednesday's announcement sets no separate date for publishing diagnostic accuracy results.
Adrian Kessler






